What Happens When You Stop a GLP-1?

It is the question that matters more than almost any other for anyone considering a GLP-1 medication: what happens when you stop? Unlike many topics in this field, this one has reasonably direct trial evidence, and the answer is fairly consistent — though it is not the answer most people hope for.

What the trials show

When people in the major trials discontinued their medication, a substantial portion of lost weight returned over the following months. The clearest data comes from two withdrawal studies:

Trial	What was withdrawn	Outcome after stopping
STEP 1 extension (semaglutide 2.4 mg)	Drug + lifestyle support	Regained ~two-thirds of lost weight by one year
SURMOUNT-4 (tirzepatide)	Switched to placebo	Mean 14% weight regain over 52 weeks, vs 5.5% further loss on continued drug

In the STEP 1 extension, mean weight loss was 17.3% at week 68 on semaglutide; by week 120, a year after withdrawal, the net loss had shrunk to about 5.6%. In SURMOUNT-4, those who continued tirzepatide kept nearly all their loss, while those switched to placebo regained most of it.

This is not a failure of willpower. GLP-1 drugs work in part by changing appetite signaling and how full you feel. Remove the drug and those signals revert toward their prior set point, and so does intake.

The honest framing: for most people, GLP-1 medications behave like a treatment for an ongoing condition, not a temporary course that resolves it. Stopping tends to mean regain.

Why regain happens

• Appetite suppression fades as the drug clears, and hunger signals return.
• The body defends a higher fat mass through metabolic and hormonal adaptations after weight loss.
• Habits built during treatment are not always enough to hold the new weight on their own.

In both trials, the cardiometabolic improvements seen on treatment — blood pressure, lipids, glucose markers — also drifted back toward baseline as weight returned.

What might change the picture

The most interesting open question is whether stopping after weight is lost, combined with strong nutrition and strength training, can blunt regain. The evidence here is thinner and mixed. Some people clearly hold more of their loss than others, and structured support seems to help, but the trials do not yet let us predict who will succeed. Tapering rather than stopping abruptly, and using the lowest effective maintenance dose, are being studied as middle paths.

The takeaway

The trials give a clearer answer here than in most areas: stopping a GLP-1 usually leads to meaningful regain — about two-thirds of lost weight within a year in the STEP 1 extension — because the drug treats an ongoing biological process rather than curing it. That is not a reason to avoid these medications, but it is a reason to go in understanding that the decision is closer to managing a chronic condition than completing a short program.

Sources

• Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (Diabetes, Obesity and Metabolism, 2022)
• Continued Treatment With Tirzepatide for Maintenance of Weight Reduction: The SURMOUNT-4 Randomized Clinical Trial (JAMA, 2024)